. 2018 Jan 1;3(1):1–9. doi: 10.1089/trgh.2017.0026

Table 2.

Case Studies of Benign Breast Neoplasia in Transgender Patients Receiving Feminizing Gender-Affirming Hormone Therapy

First author (year)	Tumor type	Age at diagnosis	Risk factors for breast cancer	Hormone, receptor status	Feminizing GAHT, type, dose, and duration
Kanhai et al. (1999)³¹	Fibroadenoma	41	No documented risk factors	Not reported	Oral cyproterone acetate (50 mg/day; 19 years)
Kanhai et al. (1999)³¹	Fibroadenoma	41	No documented risk factors	Not reported	Ethinyl estradiol (0.1 mg/day; 19 years)
Lemmo et al. (2002)³²	Fibroadenoma	35	(−) History of cancer (patient)	Not reported	Oral cyproterone acetate (unknown dose; 13 years)
Lemmo et al. (2002)³²	Fibroadenoma	35	(−) History of cancer (patient)	Not reported	Ethinyl estradiol (unknown dose; 20 years)
Walsh et al. (2014)³³	Angiolipoma	61	No documented risk factors	Not reported	Unknown type, unknown means of administration (unknown dose; 18 months)
O'Bryan et al. (2018)	Myofibroblastoma	76	(−) Family history	(+) Estrogen	Estradiol patch (100 mcg/day; 13 months)
O'Bryan et al. (2018)	Myofibroblastoma	76	(+) Risk factor for cancer [former smoker]	(+) Progesterone	Estradiol patch (100 mcg/day; 13 months)